Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Applied Molecular Transport (AMT) has entered into a research collaboration and license agreement with Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ), for a potential inflammatory bowel diseases (IBS) therapy.
Subscribe to our email newsletter
Facilitated by Johnson & Johnson Innovation, the deal grants Janssen an exclusive, worldwide license for an orally administered biopharmaceutical product candidate specifically designed to treat IBS.
AMT uses its TRANSINT technology to develop oral biopharmaceuticals and RNA therapeutics for local gastrointestinal targeting or systemic release.
Applied Molecular Transport founder and chief business officer Tahir Mahmood said: "The gastrointestinal submucosa is a region rich in immune targets that modulate local and systemic diseases, including inflammation.
"The role of molecular trafficking technologies as engines for the development of next-generation, orally administered biopharmaceuticals has been recognized as a significant area of opportunity in the pharmaceutical industry."
As part of the deal, AMT is eligible to receive upfront license fees, support for research activities, and milestone payments upon achievement of defined development, regulatory and commercialization milestones, plus tiered royalties on worldwide sales.